InvestorsHub Logo
Followers 523
Posts 6631
Boards Moderated 1
Alias Born 07/24/2012

Re: None

Thursday, 10/25/2012 9:06:29 PM

Thursday, October 25, 2012 9:06:29 PM

Post# of 130503
Amarantus' license for NuroPro, our clinical-stage Parkinson's disease diagnostic blood test, has several potential positive benefits for our MANF Parkinson's program including the identification of patients most likely to respond to MANF treatment. We intend to immediately pursue a partnering strategy for NuroPro and expect to update the marketplace once definitive agreements are reached. NuroPro could become a significant source of revenue for the Company within a relatively short period of time and its further development could have a major impact on the way Parkinson's disease is diagnosed and managed by physicians.